Abstract:Abstract Unleashing the pro-apoptotic effects of p53 by pharmacologic inhibition of MDM2 has been an attractive therapeutic strategy in hematologic malignancies with intact p53. However, concerns were expressed regarding the selection of TP53-mutant subclones with potential GOF activities. It is not clear whether pre-existing sub-clones with TP53 mutation(s) undergo malignant transformation or clonal expansion after exposure to MDM2i therapy. We generated traceable conditional somatic TP53R172H mutant mouse models to monitor and track the expansion of p53 mutant myeloid cells over the course of therapy with MDM2i. We combined a myeloid-specific Cre line, LysM-CreERT2, or Mx1-cre with a conditional knock-in mutant Trp53 allele that constitutively expresses WT Trp53 and converts to mutant (Mut) Trp53R172H upon Cre-mediated recombination. To trace the recombined hematopoietic cells, we used the Rosa26mTmG reporter allele as previously described and performed a pulse-chase experiment. LysM-CreERT2;mTmG;Trp53R172H/fx mice did not develop leukemia after 1 year upon multiple tamoxifen inductions, suggesting that Trp53 mutation in mature myeloid cells is not leukemogenic. Having a GFP marker in myeloid cells allowed us to monitor the population of GFP+ myeloid cells in peripheral blood after each tamoxifen pulse. The GFP+ cells slowly disappeared from peripheral blood over time and were completely undetectable after 1 month following induction, suggesting that p53 mutation in myeloid cells does not extend the half-life of myeloid cells. Next, to assess if the Mdm2i therapy may cooperate with Trp53 mutation and transform the myeloid cells to AML, we induced the p53 mutation by tamoxifen injection and treated LysM-CreERT2;mTmG;Trp53fx/fx and LysM-CreERT2;mTmG;Trp53R172H/fx mice with the MDM2i, idasanutlin, for 10 days. There were no significant differences in the number of GFP+ myeloid cells between the two groups at baseline, however, in the p53-mutant group, the population of GFP+ cells was significantly decreased and in some mice was fully eradicated after MDM2i treatment. We transplanted LysM-CreERT2;mTmG;Trp53R172H/fx and control mice with syngeneic MLL-AF9 transformed leukemia cells and treated them with idasanutlin 1 week after transplant. Strikingly, the population of GFP+ cells was highly expanded in p53 mutant mice transplanted with AML after MDM2i treatment, suggesting that MDM2 inhibition promotes the proliferation of p53-mutant myeloid subclones in the context of AML. We sorted the GFP+ cells and transplanted them into syngeneic mice. No leukemia arose after transplantation. We here established the first in vivo model of p53-mutant clonal hematopoiesis using a new p53 mutant conditional allele. The expanded population of p53 mutant subclone did not transform into AML. However, in the presence of fully transformed AML cells, the p53 mutant clonal hematopoiesis expanded. This finding is consistent with reports of transitory expansion of p53 mutant cells in patients with myelofibrosis treated with MDM2 inhibitor. Citation Format: Russell Pourebrahim, Rafel Heinz Montoya, Lauren Ostermann, Michael Andreeff. Murine models of mutant p53 clonal hematopoiesis elucidate mechanisms of expansion of p53 mutant subclones by MDM2 inhibition [abstract]. In: Proceedings of the AACR Special Conference: Acute Myeloid Leukemia and Myelodysplastic Syndrome; 2023 Jan 23-25; Austin, TX. Philadelphia (PA): AACR; Blood Cancer Discov 2023;4(3_Suppl):Abstract nr A06.

Tumorigenesis Of Murine Erythroleukemia Cell Line Transfected With Exogenous P53 Gene

Exogenous Wild-Type P53 Gene Improved Survival Of Nude Mice Injected With Murine Erythroleukemia Cell Line Through Amelioration Of Hemorheological Changes

Wild type p53 gene causes reorganization of cytoskeleton and, therefore, the impaired deformability and difficult migration of murine erythroleukemia cells.

Supplemetal Data from Genetic Ablation of Rbm38 Promotes Lymphomagenesis in the Context of Mutant P53 by Downregulating PTEN

Data from Genetic Ablation of <i>rbm38</i> Promotes Lymphomagenesis in the Context of Mutant P53 by Downregulating PTEN

High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene

Change From Promotion To Inhibition On Apoptosis In Hepatoma Cells Transferred Wild-Type P53 Gene

Alterations Of The P53 Tumor-Suppressor Gene In Transformed Mouse-Liver Cells

Effect of Transfection with p53 Gene on Malignancy of Human Hepotacellular Carcinoma Cell Lines

Modeling the Etiology of p53-mutated Cancer Cells

Effects of genetic background on tumorigenesis in p53-deficient mice

[Effect of Wt P53 Gene Transfection on Sensitivity of Hyperthermia in C6 Glioma Cells].

Effect of transfection of wild-type p53 gene on sensitivity of T cell lymphoma to chemotherapy

Abstract A06: Murine models of mutant p53 clonal hematopoiesis elucidate mechanisms of expansion of p53 mutant subclones by MDM2 inhibition

Gain of Function of a p53 Hot Spot Mutation in a Mouse Model of Li-Fraumeni Syndrome

Transcriptomic alterations including p53 pathway dysregulation prime DNMT3A mutant cells for transformation

Mutation of Mouse P53 Ser23 and the Response to Dna Damage

BAC transgenic mice provide evidence that p53 expression is highly regulated in vivo

Distinct effects of various p53 mutants on differentiation and viability of human K562 leukemia cells

The MMTV/c-myc Transgene and P53 Null Alleles Collaborate to Induce T-cell Lymphomas, but Not Mammary Carcinomas in Transgenic Mice.